Dearborn Partners LLC Invests $3.61 Million in Medtronic PLC $MDT

Dearborn Partners LLC acquired a new stake in shares of Medtronic PLC (NYSE:MDT) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 46,112 shares of the medical technology company’s stock, valued at approximately $3,607,000.

Several other large investors also recently bought and sold shares of the business. Madison Asset Management LLC grew its holdings in shares of Medtronic by 15.0% in the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock valued at $18,752,000 after purchasing an additional 25,527 shares during the period. First Eagle Investment Management LLC increased its position in Medtronic by 0.4% during the fourth quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company’s stock worth $939,009,000 after purchasing an additional 40,196 shares during the last quarter. Gradient Investments LLC raised its stake in Medtronic by 3.9% during the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock worth $38,842,000 after purchasing an additional 18,509 shares during the period. Czech National Bank raised its stake in Medtronic by 4.7% during the second quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock worth $28,589,000 after purchasing an additional 16,292 shares during the period. Finally, Cerity Partners LLC boosted its holdings in Medtronic by 12.7% in the 4th quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock valued at $75,988,000 after purchasing an additional 89,111 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of MDT opened at $90.04 on Friday. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The stock has a market cap of $115.24 billion, a PE ratio of 24.14, a P/E/G ratio of 2.47 and a beta of 0.55. The firm has a 50-day simple moving average of $85.34 and a two-hundred day simple moving average of $85.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.54 by $0.01. The firm had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, analysts forecast that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.2%. Medtronic’s payout ratio is presently 77.21%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. UBS Group raised shares of Medtronic from a “neutral” rating to a “buy” rating and increased their price target for the company from $85.00 to $100.00 in a research note on Tuesday, July 28th. Mizuho decreased their price objective on Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Wednesday, June 3rd. Evercore set a $105.00 price objective on Medtronic in a report on Monday, July 6th. TD Cowen lowered their price objective on Medtronic from $119.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Finally, Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Eighteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $99.38.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is owned by company insiders.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a Buy rating, implying substantial upside from recent trading levels. The firm expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance, potentially providing a near-term catalyst. Medtronic price target raised by Needham
• Positive Sentiment: Analysts expect continued growth across Medtronic’s Cardiovascular, Neuroscience and Diabetes businesses. Cardiovascular performance and expanding renal-denervation activity are highlighted as important growth opportunities. Medtronic Q1 estimates and guidance
• Positive Sentiment: Medtronic reaffirmed its dividend trajectory, approving a $0.72-per-share fiscal 2027 second-quarter dividend. The ongoing dividend supports the stock’s appeal to income-oriented investors. Medtronic dividend update
• Positive Sentiment: Recent coverage points to strengthening device momentum and a potential rebound, while Medtronic remains viewed as a relatively inexpensive, diversified alternative to faster-growing surgical-robotics companies. Medtronic device momentum

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).